Our results show that, considering the observed consequences of FN on chemotherapy delivery (dose adjustments, delays, dropped cycles), and the known associated negative impact of such consequences on the efficacy of treatment, patients with breast cancer and NHL who are to receive moderate or high risk chemotherapy regimens may benefit from better access to primary prophylaxis with G-CSF. This evidence concerns the gene CSF3 and breast cancer.